Latest Breaking News On - Recourse royalty - Page 1 : vimarsana.com

Resubmission of NDA On Track for Early Q2 24— Cash Runway into 2025, including through Potential FDA Approval in Early Q4 24 Company to host conference call today at 8:30amET DUBLIN, Ireland and CHICAGO, March 28, 2024 (GLOBE NEWSWIRE) Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today r

United statesJudy matthewsCorey fishmanDrug administrationRecourse royaltyCash runwayChief executiveSpecial protocol assessmentResistant enterobacteralesComplete response letterFinancial advisorFull yearPrescription drug user fee actExchangeable senior subordinated notesIterum therapeuticsQualified infectious disease product